779 patents
Page 7 of 39
Utility
Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
29 Jun 23
A combination of temsirolimus and trastuzumab in the treatment of cancer is provided.
Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
Filed: 22 Jul 22
Utility
Beta-lactamase Inhibitors and Uses Thereof
29 Jun 23
β-Lactamase inhibiting compounds, therapeutic methods of using the β-lactamase inhibiting compounds, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed.
Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
Filed: 28 Feb 23
Utility
Recombinant Vaccinia Virus
29 Jun 23
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (RVV), compositions comprising the RVV, and use of the RVV or composition for inducing oncolysis in an individual having a tumor.
Joseph John Binder, Michael Dale Eisenbraun, Douglas Hanahan, David H. Kirn, Clare Lees, Prajit Limsirichai, Liliana Maruri Avidal
Filed: 5 Jan 21
Utility
Solid State Forms of (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
29 Jun 23
The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Filed: 17 Feb 23
Utility
Glycoconjugation Process
29 Jun 23
The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
Mingming Han, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad
Filed: 1 Mar 23
Utility
Azalactam compounds as HPK1 inhibitors
27 Jun 23
Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
Filed: 30 Apr 21
Utility
Recombinant vaccinia virus and methods of use thereof
27 Jun 23
The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus, compositions comprising the vaccinia virus, and use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.
David H. Kirn, Liliana Maruri Avidal, Prajit Limsirichai
Filed: 10 Feb 20
Utility
Benzimidazole derivative compounds and uses thereof
30 May 23
Scott William Bagley, Agustin Casimiro-Garcia, Xiayun Cheng, Jennifer Elizabeth Davoren, Rajiah Aldrin Denny, Brian Stephen Gerstenberger, Frank Eldridge Lovering, Mihir Dineshkumar Parikh, Joseph Walter Strohbach, John Isidro Trujillo
Filed: 18 Dec 20
Utility
Purification of antibody drug conjugates using a sodium phosphate gradient
30 May 23
Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.
Durgesh V. Nadkarni, Jeffry R. Borgmeyer, He Meng, Qingping Jiang
Filed: 7 Dec 16
Utility
Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
25 May 23
The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof.
Padmavani Bezawada, Benjamin Joseph Burke, Emma Louise Hawking, Robert Louis Hoffman, Robert Steven Kania, Jonathan Richard Lillis, Matthew Nathan O'Brien Laramy, Klimentina Dimitrova Pencheva, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst
Filed: 3 Mar 21
Utility
Co-treatment with CDK4/6 and CDK2 Inhibitors to Suppress Tumor Adaptation to CDK2 Inhibitors
25 May 23
The invention provides a method for treating a disease or disorder, and preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a CDK2 inhibitor, and a therapeutically effective amount of a CDK4/6 inhibitor, wherein the CDK4/6 inhibitor prevents rebound phosphorylation mediated by CDK4 and/or CDK6 in response to the inhibition of CDK2.
Mansi Arora, Stephen George Dann, Nichol Lee Goodman Miller, Sabrina Spencer, Todd Lee VanArsdale
Filed: 7 Apr 21
Utility
Crystalline Forms of 3-CYANO-1-[4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRAZIN-4-YL]-1H-PYRAZOL-1-YL]CYCLOBUTANEACETONITRILE, and Use Thereof
25 May 23
The present invention discloses novel crystalline forms of (1R,3R)-3-(cyanomethyl)-3-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile, Form 1 anhydrous free base and Form 2 monohydrate, pharmaceutical composition containing them, preparations thereof and uses thereof.
Andrew James JENSEN
Filed: 5 Apr 21
Utility
Aminopyrimidinyl derivatives
23 May 23
Brian Stephen Gerstenberger, Wenhua Jiao, Manjinder Singh Lall, Ricardo Lira, Mark Edward Schnute
Filed: 30 Jun 21
Utility
Methods of Treating Coronavirus Disease 2019
18 May 23
The present invention is related to the discovery of new methods for treating the pathologic inflammatory response associated with patients infected with SARS-CoV-2 comprising administering orally to the patient in need of such treatment a therapeutically effective amount of a JAK inhibitor, a JAK/TYK inhibitor, or an IRAK4 inhibitor, or a combination thereof.
Michael Corbo, Spencer Ian Danto, Tamas Andras Koncz, Elena Peeva, Hernan Valdez, V, Michael Steven Vincent, Cara Margaret May Williams
Filed: 1 Apr 21
Utility
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
16 May 23
Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. Mcfaddin, Megan L. Mckenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
Filed: 1 Dec 20
Utility
Boron Containing PDE4 Inhibitors
11 May 23
Tsutomu Akama, David Clive Blakemore, Robert Toms Jacobs, Peter Jones, David Christopher Limburg, Martins Sunday Oderinde, Matthew Alexander Perry, Jacob John Plattner, Joseph Walter Strohbach, Rubben Federico Torella, Thean Yeow Yeoh, Yasheen Zhou
Filed: 15 Dec 22
Utility
N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
11 May 23
Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
Filed: 8 Sep 22
Utility
ANTI-GUCY2C Antibodies and Uses Thereof
11 May 23
The present invention is directed to antibodies that specifically bind to GUCY2c and methods of using such antibodies in the diagnosis and/or treatment of cancer.
Chew Shun CHANG, Divya MATHUR, Adam Reid ROOT
Filed: 14 Oct 21
Utility
Tricyclic Compounds and Their Use As Phosphodiesterase Inhibitors
11 May 23
Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
Filed: 12 Oct 22
Utility
Melanocortin 4 receptor antagonists and uses thereof
9 May 23
Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
Filed: 8 Jun 21